Merrimack Pharmaceuticals Stock News

U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Wednesday. Here are some big stocks recording gains in today’s session. Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) sh

Biotech penny stocks with upcoming events to watch in November 2022. The post 3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240% appeared first on Penny Stocks to Buy, Picks, News and Informa

U.S. stocks traded lower this morning as investors focused on the outcome of the midterm elections, with the Dow Jones dropping around 250 points on Wednesday. Following the market opening Wednesday,

The stock price of Merrimack Pharmaceuticals (MACK) skyrocketed by over 240% today. This is why.

Biotech penny stocks with upcoming events to watch in November 2022. The post 3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240% appeared first on Penny Stocks to Buy, Picks, News and Informa

Shares of Merrimack Pharmaceuticals Inc. MACK, +224.14% skyrocketed 199.5% toward a 4 1/2-year high in morning trading Wednesday, after the France-based biopharmaceutical company Ipsen IPSEY, +1.39% I

MACK has a $225m milestone if its drug Onivyde works in first-line pancreatic cancer (already approved in second-line). The stock has been badly misvalued because the vast majority of pancreatic cance

Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case

Merrimack Pharmaceuticals press release (MACK): FY GAAP EPS of -$0.18.As of December 31, 2021, Merrimack had cash and cash equivalents and investments of $14.2 million, compared to…

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2021 financial results for the period ended December 31, 2021 . “During 2021 we have continued to reduce our operating expenses and remain

Renaissance Technologies LLC reduced its holdings in shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) by 45.8% during the second quarter, HoldingsChannel.com reports. The fund owned 101,970 shares of the biopharmaceutical companys stock after selling 86,191 shares during the quarter. Renaissance Technologies LLCs holdings in Merrimack Pharmaceuticals were worth $652,000 as of its most recent filing with []

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended J

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2020 Financial Results

Merrimack Reports Second Quarter 2020 Financial Results